

## Halogen-substituted Drugs and their Intermolecular Interactions

Penelope W. Coddling, *Department of Chemistry, University of Victoria, Victoria, BC, V8W 3V6, Canada.* E-mail: pcoddling@uvic.ca

Halogen substitution is an important tool in drug design. Halogenation alters physicochemical properties and enhances the potency of membrane-soluble anesthetics. The presence and identity of halogen (X) substituents pendant on an aromatic nucleus in anticonvulsant and anxiolytic drugs have significant consequences for activity. Explanations of the Structure-activity effects of halogens have been limited to considerations of membrane solubility and the steric effects of X substituents on aromatic rings even though much is known about the effect of halogens on crystal packing. Crystal engineering originated with a study of the packing of Cl substituents [1]. Subsequent investigations using the CSD [2] and theoretical calculations have established the intermolecular interactions important in crystals of halogen compounds: (a) X atoms are potential H-bond acceptors able to interact with strong and weak H-bond donors [3], although the evidence is equivocal for C-F as a H-bond acceptor [4]; (b) C-H...X interactions are weakly attractive yet highly dependant on the molecular environment of the halogen [5, 6] and (c) X...aromatic ring and X...H are stronger interactions than X...X [7]. Structure activity relationships in CNS drugs will be interpreted in light of these intermolecular interactions to explain identify key factors for binding.

[1] Schmidt G.M.J., *J.Chem Soc.*, 1964, 2014. [2] Allen F.H., et al., *J. Chem Inf. Comput. Sci.*, 1991, **31**, 187. [3] Brammer L, et al., *Crystal Growth & Design*, 2001, **1**, 277. [4] Dunitz J.D., *Chembiochem*, 2004, **5**, 614. [5] Lommerse J.P.M, et al., *J. Am. Chem. Soc.*, 1996, **118**, 3108. [6] van den Berg J.-A. , Seddon K.R., *Crystal Growth & Design*, 2003, **3**, 643. [7] Price S.L, et al., *J. Am. Chem. Soc.*, 1994, **116**, 4910.

**Keywords:** structural systematics, drug design, halogens